.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,686,786

« Back to Dashboard
Patent 7,686,786 protects RYZODEG 70/30, TRESIBA, SAXENDA, LEVEMIR FLEXTOUCH, NORDITROPIN FLEXPRO, and NOVOLOG FLEXTOUCH, and is included in six NDAs.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 7,686,786

Title:Dial-down mechanism for wind-up pen
Abstract: The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising dial-up cam arranged to receive and engage with a dial-up key, wherein the dial-up cam and the dial-up key are adapted to, upon rotation of a dose setting member in a first direction, cooperate to strain the torsion spring of the injection device, and a dial-down cam arranged to receive and engage with a dial-down key, wherein the dial-down cam and the dial-down key are adapted to, upon rotation of the dose setting member in a second direction, cooperate to release the torsion spring of the injection device, the second rotation direction being opposite to the first rotation direction.
Inventor(s): Moller; Claus Schmidt (Fredensborg, DK), Enggaard; Christian Peter (Vejby, DK), Radmer; Bo (Hillerod, DK), Markussen; Tom Hede (Bagsv.ae butted.rd, DK)
Assignee: Novo Nordiks A/S (Bagsvaerd, DK)
Application Number:11/665,486
Patent Claim Types:
see list of patent claims
Device; Delivery;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 6th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
RYZODEG 70/30
insulin aspart; insulin degludec
SOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYes7,686,786► subscribeY
Novo Nordisk Inc
TRESIBA
insulin degludec
SOLUTION;SUBCUTANEOUS203314-001Sep 25, 2015RXNo7,686,786► subscribeY
Novo Nordisk Inc
TRESIBA
insulin degludec
SOLUTION;SUBCUTANEOUS203314-002Sep 25, 2015RXYes7,686,786► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,686,786

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04077900Oct 21, 2004
PCT Information
PCT FiledOctober 20, 2005PCT Application Number:PCT/EP2005/011285
PCT Publication Date:May 04, 2006PCT Publication Number: WO2006/045526

International Patent Family for Patent: 7,686,786

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2389514► subscribe
Russian Federation2007114761► subscribe
South Korea101300496► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc